These findings identify the RIPK1-MCU pathway as a promising target to treat colorectal cancer.<b>Significance:</b> RIPK1-mediated cell proliferation through MCU is a central mechanism underlying colorectal cancer progression and may prove to be an important therapeutic target for colorectal cancer treatment.<i></i>.
These results indicate that TNF plays a key role in determining the cytotoxic effectiveness of SN38 in colorectal cancer and suggests a re-evaluation of TNF-based interventions to enhance therapeutic efficacy.<b>Implications:</b> The capacity of RIP1 to influence drug sensitivity suggests RIP1 may have biomarker potential.<i></i>.
The RIPK1 and CASP7 polymorphisms can be considered as possible prognostic markers for survival after curative resection in patients with colorectal cancer.